Unknown

Dataset Information

0

Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers.

ABSTRACT: We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR genetic screens identify combinations causing apoptotic anti-tumor activity. The most potent combination, concurrent inhibition of RAF (RAFi) and ERK (ERKi), is highly synergistic at low doses in cell line, organoid, and rat models of PDAC, whereas each inhibitor alone is only cytostatic. Comprehensive mechanistic signaling studies using reverse phase protein array (RPPA) pathway mapping and RNA sequencing (RNA-seq) show that RAFi/ERKi induced insensitivity to loss of negative feedback and system failures including loss of ERK signaling, FOSL1, and MYC; shutdown of the MYC transcriptome; and induction of mesenchymal-to-epithelial transition. We conclude that low-dose vertical inhibition of the RAF-MEK-ERK cascade is an effective therapeutic strategy for KRAS mutant PDAC.

SUBMITTER: Ozkan-Dagliyan I 

PROVIDER: S-EPMC7393480 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

We address whether combinations with a pan-RAF inhibitor (RAFi) would be effective in KRAS mutant pancreatic ductal adenocarcinoma (PDAC). Chemical library and CRISPR genetic screens identify combinations causing apoptotic anti-tumor activity. The most potent combination, concurrent inhibition of RAF (RAFi) and ERK (ERKi), is highly synergistic at low doses in cell line, organoid, and rat models of PDAC, whereas each inhibitor alone is only cytostatic. Comprehensive mechanistic signaling studies  ...[more]

Similar Datasets

Genomics Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS-mutant Cancers
| PRJEB38063 | ENA
Unknown Vertical Inhibition of the RAF-MEK-ERK Cascade Induces Myogenic Differentiation, Apoptosis, and Tumor Regression in <i>H/NRAS<sup>Q61X</sup></i> Mutant Rhabdomyosarcoma.
| S-EPMC8742779 | biostudies-literature
Unknown Direct Targeting of the Raf-MEK-ERK Signaling Cascade Inhibits Neuroblastoma Growth.
| S-EPMC9497977 | biostudies-literature
Unknown Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers.
| S-EPMC11301402 | biostudies-literature
Unknown Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.
| S-EPMC5941622 | biostudies-literature
Unknown Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers.
| S-EPMC6452642 | biostudies-literature
Unknown SHOC2 phosphatase-dependent RAF dimerization mediates resistance to MEK inhibition in RAS-mutant cancers.
| S-EPMC6557854 | biostudies-other
Unknown ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
| S-EPMC6878763 | biostudies-literature
Unknown Targeting KRAS Mutant Cancers via Combination Treatment: Discovery of a Pyridopyridazinone pan-RAF Kinase Inhibitor.
| S-EPMC8155235 | biostudies-literature
Unknown PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling.
| S-EPMC3178450 | biostudies-literature